Total Reports
87
Above-median volume
Breed profile · FDA CVM July 2026 extract
Adverse-event filings for Dogo Argentino (Dog) in the FDA Center for Veterinary Medicine openFDA extract. Browse dog breeds, reactions, and outcomes below.
By recorded gender -- every report on file for Dogo Argentino, no filtering.
Data updated September 2026
The verdict
According to the FDA Center for Veterinary Medicine openFDA adverse-event extract, Dogo Argentino ranks #243 of 510 by total reports (87) and #208 of 275 by death-coded share (3.4%). National dual: Retriever - Labrador is #1 of 510 by total adverse-event reports (93,675) at death-coded-share rank 195 of 275 breeds with at least 50 reports (3.7%); separately, Atlantic Salmon (Salmo salar) is #1 highest death-coded share at 99.0% (report rank #233).
Report volume reflects how common a breed or drug is and how often owners and vets file — not actual risk. Death-coded share ranks are limited to entries with enough reports to be meaningful. The two maps do not agree at #1.
Release-over-release change
PlainBreed reconstructed the prior snapshot from dated openFDA partitions through 2025 Q4, then compared it with the 2026-07-27 openFDA export. Dogo Argentino has 87 reports now versus 86 in that prior snapshot: 1 more (1.2%).
This compares reported-event counts in two source snapshots. It does not establish a change in real-world risk, product safety, or disease incidence.
Subscribe to Dogo Argentino changesTotal Reports
87
Above-median volume
Deaths Reported
3
of 87 reports
Death-coded share of reports
3.4%
Lowest death-coded share
Avg Age at Report
3.6 yr
36.3 kg avg weight
3.4% of 87 dogo argentino reports involved a death outcome.
Read alongside breed popularity, veterinary access, and owner awareness, these shape how many events ever reach the FDA. The comparison line marks the cross-breed median death-coded share (4.8%) among breeds with 50 or more reports; values above it suggest higher reporting bias toward severe outcomes, not necessarily higher true mortality.
| Year | Reports | Trend |
|---|---|---|
| 2011 | 1 | |
| 2012 | 4 | |
| 2013 | 4 | |
| 2014 | 5 | |
| 2015 | 6 | |
| 2016 | 12 | |
| 2017 | 2 | |
| 2018 | 7 | |
| 2019 | 7 | |
| 2020 | 5 | |
| 2021 | 4 | |
| 2022 | 4 | |
| 2023 | 10 | |
| 2024 | 4 | |
| 2025 | 11 | |
| 2026 | 1 | |
Signature read: Dogo Argentino's 3.4% death-coded share is in the lower third of the ≥50-report cohort (median 4.8%). According to FDA CVM filings indexed on PlainBreed as of July 2026 extract, Dogo Argentino sits at #243 of 510 by report volume among all breeds and #176 of 298 among dog breeds, with 87 reports and 3 (3.4%) death-coded. On death-coded share among breeds with ≥50 reports, it ranks #208 of 275. Mean age at report: 3.6 years, average weight 36.3 kg (80.0 lbs).
Top reported signs: Vomiting (24), Lack of efficacy (ectoparasite) - flea (9), Diarrhoea (9). Most-referenced drug: Milbemycin Oxime + Spinosad (39 reports), followed by Fluralaner 13.64% 12-Week Chew (10) and Spinosad (8).
Outcome coding on 87 status-recorded reports is dominated by Recovered/Normal (34.5%). Annual submissions ranged 1-2,026 across 16 years on file.
Showing 6 of 297 dog breeds in our dataset, ranked by closest report volume.
Two openFDA-derived peer sets for Dogo Argentino, both outside the Dog family so the neighborhoods are not species containment (the similar-volume list above stays within species).
Nearest other-species breeds with ≥50 reports (3.4% death-coded here).
Nearest other-species breeds by reported average weight (36.3 kg here).
What to do with this dog
A report does not prove a drug caused the reaction, and popular breeds simply generate more reports.
Compare a breed's report volume against how common the breed is before drawing conclusions. See our methodology for how the death-coded share and rankings are computed, or read breed-specific reporting patterns and FDA CVM reporting.
Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025
Informational only. FDA adverse-event reports are voluntary and do not prove causation; consult a veterinarian before acting on them. Verify with FDA CVM →